Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials

June, 2022


Introduction: In 2020, prior to COVID-19 vaccine rollout, the Coalition for Epidemic Preparedness Innovations and Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We leveraged the Brighton Collaboration list to evaluate serious adverse events of special interest observed in phase III randomized trials of mRNA COVID-19 vaccines.

C19 Vax Strategy: Geert Vanden Bossche and Robert Malone, MD

Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs

January, 2022


• mRNA vaccines promote sustained synthesis of the SARS-CoV-2 spike protein.

• The spike protein is neurotoxic, and it impairs DNA repair mechanisms.

• Suppression of type I interferon responses results in impaired innate immunity.

• The mRNA vaccines potentially cause increased risk to infectious diseases and cancer.

• Codon optimization results in G-rich mRNA that has unpredictable complex effects.


Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination

January, 2022


• Vaccination confers broader IgG binding of variant RBDs than SARS-CoV-2 infection

• Imprinting from initial antigen exposures alters IgG responses to viral variants

• Histology of mRNA vaccinee lymph nodes shows abundant germinal centers

• Vaccine spike antigen and mRNA persist for weeks in lymph node germinal centers